Ibandronate and ventricular arrhythmia risk.

ABSTRACT:

Introduction

Bisphosphonates, including ibandronate, are used in the prevention and treatment of osteoporosis.

Methods and results

We report a case of suspected ibandronate-associated arrhythmia, following a single dose of ibandronate in a 55-year-old female. ECG at presentation revealed frequent ectopy and QT/QTc interval prolongation; at follow-up 9 months later the QT/QTc intervals were normalized. Proarrhythmic potential of ibandronate was assessed with a combination of in vivo and in vitro approaches in canines and canine ventricular myocytes. We observed late onset in vivo repolarization instability after ibandronate treatment. Myocytes superfused with ibandronate exhibited action potential duration (APD) prolongation and variability, increased early afterdepolarizatio

SUBMITTER: Bonilla IM 

PROVIDER: S-EPMC4148051 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature